Oncolytics Biotech Inc.
NASDAQ:ONCYBiotechnology
+$0.03 today
- Market cap
- $50.41M
- Beta
- 1.08
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.32
Volume 0.38M
Average 1.26M
ONCY Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Oncolytics Biotech Inc.NASDAQ: ONCY
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow grows, but more slowly than its trailing trend
Q1 FY2026 financing cash flow of CA$10.62M rose 80.3% year over year, behind the +114.9% change in trailing-twelve-month financing cash flow. Sequentially, it rose 196.6% from the prior quarter. Over 3 fiscal years it compounded at +16.7% a year.
Context
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +80.3% toward the trailing-twelve-month pace of +114.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
CAD · from the cash flow
- Latest · FY2025
- 19.37M CAD
- Year-over-year change
- +192.0%
- 4-year CAGR
- -12.5%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.37M | +192.0% |
| FY2024 | 2024-12-31 | 6.64M | -79.3% |
| FY2023 | 2023-12-31 | 31.99M | +162.1% |
| FY2022 | 2022-12-31 | 12.21M | -63.0% |
| FY2021 | 2021-12-31 | 33.02M | — |
Financing Cash Flow vs competitors
How ONCY compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +114.9% is the 5th highest of 8, against a peer median of +255.3%.
- Over three fiscal years its annual growth of +16.7% compares with a peer median of +19.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $107.35M USD | — | +221.5% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $94.38M USD | +72496.9% | +9.1% | 1320.9% |
| LTM Mar 2026 | $69.59M USD | +16083.5% | +247.3% | 44.3% | |
| LTM Mar 2026 | $38.95M USD | -57.9% | — | 519.7% | |
| LTM Mar 2026 | $31.36M USD | +111.9% | +29.6% | 395.1% | |
| LTM Mar 2026 | CA$23.71M CAD | +114.9% | +16.7% | — | |
| LTM Mar 2026 | $14.08M USD | +1110.6% | -12.6% | 10506.7% | |
| LTM Mar 2026 | $7.06M USD | +255.3% | -53.4% | — | |
| LTM Mar 2026 | $5.59M USD | -2029.0% | — | — | |
| Peer median (excluding ONCY) | — | +255.3% | +19.4% | 519.7% | |
Competitors are the stored peer set for ONCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.3M) | (24.84M) | (27.75M) | (31.71M) | (39.46M) |
| Depreciation & Amortization | 452.07K | 392K | 403K | 424K | 96.05K |
| Deferred Income Tax | 408.56K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.83M | 2.38M | 2.07M | 2.72M | 4.26M |
| Change in Working Capital | (907.99K) | 391K | 1.77M | 3.54M | 1.62M |
| Accounts Receivables | (776.39K) | 345K | 506K | (53K) | 4.03M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (131.59K) | 46K | 1.26M | 3.59M | (2.41M) |
| Other Non-Cash Items | 91.73K | (1.68M) | (4.93M) | (1.94M) | 5.89M |
| Operating Cash Flow | (22.43M) | (23.36M) | (28.45M) | (26.97M) | (27.6M) |
| Capital Expenditures | (285.95K) | (55K) | (8K) | (239K) | (8.23K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (20.35M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 20.23M | 0 | 0 |
| Other Investing Activities | 0 | (20.35K) | 0 | 0 | 0 |
| Investing Cash Flow | (285.95K) | (20.4M) | 20.22M | (239K) | (8.23K) |
| Debt Repayment | (366K) | (381K) | (407K) | (348K) | 0 |
| Common Stock Issued | 32.91M | 12.57M | 31.62M | 6.92M | 19.41M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 469.68K | 12K | 781K | 65K | (37.05K) |
| Financing Cash Flow | 33.02M | 12.21M | 31.99M | 6.64M | 19.37M |
| Effect of Forex Changes | (253.25K) | 1.96M | (522K) | 1.6M | 166.03K |
| Net Change in Cash | 10.04M | (29.6M) | 23.25M | (18.97M) | (8.06M) |
| Free Cash Flow | (22.72M) | (23.41M) | (28.46M) | (27.21M) | (27.6M) |
Oncolytics Biotech Inc.
NASDAQ:ONCY
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.